The global nanomedicine market size is expected to reach around US$ 964.15 billion by 2030 from US$ 377.37 billion in 2021 and is expected to grow at an impressive double-digit rate of 11% from 2022 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global nanomedicine market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2022 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1633
Report Highlights:
- Based on the application, the regenerative medicinesegment dominated the global nanomedicine market in 2021 with largest market share. The goal of regenerative medicine is to create and implement treatments to mend tissues and organs and restore function that has been lost due to ageing, injury, disease, or abnormalities. In many aspects, the human body has the natural ability to heal itself.
- On the basis of indication, the oncological diseasessegment holds the largest market share the global nanomedicine market in 2021. Nanomedicine has the potential to change existing cancer therapy and diagnosis approaches in the field of oncology. Nanotechnology based cancer medicines and diagnostics have made significant progress, and there are countless fresh innovations in the process.
- North America is the largest segment for nanomedicine market in terms of region. The nanomedicine market’s expansion is fueled by an increase in the number of participants and widespread adoption of innovative technologies.
- Asia-Pacific region is the fastest growing region in the nanomedicine market. The region is expected to benefit from a strong government drive to expand healthcare facilities through insurance plans, which is expected to generate attractive economic prospects.
Future of Nanomedicine Market
The unmet medical demands in developing countries are likely to provide growth prospects for global nanomedicine market players. In the upcoming years, developed and developing economies are likely to offer a large array of prospects for the nanomedicine market. This is owing to the fact that these countries’ economic progress has provided patients with increased purchasing power as a result of rising disposable incomes. The employment of innovative tools will be enabled by improved healthcare infrastructure, which will attract to the population’s significant unmet medical demands in the near future.
COVID-19 Impact Analysis:
- The utilization of nanotechnology opens up new possibilities for the development of revolutionary COVID-19 and other viral infection prevention, diagnosis, and treatment procedures.
- COVID-19 was managed through the development of nano based materials for treatments and vaccine development such as disinfectants, diagnostic systems, personal protective equipment, and nanocarrier systems.
Key Developments in the Marketplace:
- In January 2022, NaNotics LLC and Mayo Clinics announced a collaboration to create a NaNot that targets the soluble version of PD-L1, a tumor-induced immune inhibitor.
- A EUR 12 million grant was awarded in March 2021 to a collaboration between two Barcelona universities and the University of Manchester’s Nanomedicine Lab to enhance the European medical nanotechnology industry.
- In October 2020, Medtronic PLC unveiled the Adaptix Interbody System, a guided titanium spinal implant with Titan nanoLOCK Surface Technology.
- In November 2015, Ablynx and Novo Nordisk established a global partnership and licencing agreement to develop and discover new medications using multi-specific nanobodies. This strategic agreement is predicted to promote the nanomedicine market’s growth by increasing product net yearly sales.
Research Methodology
A unique research methodology has been utilized to conduct comprehensive research on the growth of the global nanomedicine market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global nanomedicine market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.
Why should you invest in this report?
If you are aiming to enter the global nanomedicine market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for nanomedicine are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global nanomedicine market include:
- Sanofi SA
- Abbott
- Pfizer Inc.
- CombiMatrix Corporation
- GE Healthcare
- Celgene Corporation
- Johnson & Johnson Services Inc.
- Luminex Corporation
- Merck & Company Inc.
- Nanosphere Inc.
Market Segmentation:
By Modality
- Treatments
- Diagnostics
By Application
- Drug Delivery
- Diagnostic Imaging
- Vaccines
- Regenerative Medicine
- Implants
- Others
By Indication
- Oncological Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Orthopedic Diseases
- Neurological Diseases
- Urological Diseases
- Ophthalmological Diseases
- Immunological Diseases
- Others
By Nanomolecule Type
- Nanoparticles
- Metal & Metal Oxide Nanoparticles
- Liposomes
- Polymers & polymer drug conjugates
- Hydrogel nanoparticles
- Dendrimers
- Inorganic nanoparticles
- Nanoshells
- Nanotubes
- Nanodevices
Regional Analysis:
The geographical analysis of the global nanomedicine market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global nanomedicine Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global nanomedicine market in 2030?
- What is the expected CAGR for the nanomedicine market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global nanomedicine market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Nanomedicine Market
5.1. COVID-19 Landscape: Nanomedicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Nanomedicine Market, By Modality
8.1. Nanomedicine Market, by Modality Type, 2022-2030
8.1.1. Treatments
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Diagnostics
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Nanomedicine Market, By Application
9.1. Nanomedicine Market, by Application, 2022-2030
9.1.1. Drug Delivery
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Diagnostic Imaging
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Regenerative Medicine
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Implants
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Nanomedicine Market, By Indication Type
10.1. Nanomedicine Market, by Indication Type, 2022-2030
10.1.1. Oncological Diseases
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Infectious Diseases
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Cardiovascular Diseases
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Orthopedic Diseases
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Neurological Diseases
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Urological Diseases
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Nanomedicine Market, By Nanomolecule Type
11.1. Nanomedicine Market, by Nanomolecule Type, 2022-2030
11.1.1. Nanoparticles
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Nanoshells
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Nanotubes
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Nanodevices
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Nanomedicine Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Modality (2017-2030)
12.1.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.1.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Modality (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Modality (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Modality (2017-2030)
12.2.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.2.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Modality (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Modality (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Modality (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Modality (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Modality (2017-2030)
12.3.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.3.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Modality (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Modality (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Modality (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Modality (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Modality (2017-2030)
12.4.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.4.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Modality (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Modality (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Modality (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Modality (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Modality (2017-2030)
12.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Modality (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Modality (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Indication Type (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Nanomolecule Type (2017-2030)
Chapter 13. Company Profiles
13.1. Sanofi SA
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Abbott
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. CombiMatrix Corporation
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GE Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Celgene Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Johnson & Johnson Services Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Luminex Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Merck & Company Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Nanosphere Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1633
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments